Search results
Kite Pharma's CAR T-Cell Therapy Wins European Approval In Refractory Leukemia Setting
Benzinga via Yahoo Finance· 2 years agoThe European Commission has approved Gilead Science Inc (NASDAQ: GILD) company Kite Pharma's CAR...
Biotech Stock Roundup: GILD's Updates, FMTX Up on NVO Deal, SPRO Surges & More
Zacks via Yahoo Finance· 2 years agoDrug approvals and other regulatory updates are in focus in the biotech sector. The sector is also...
4 Biotech Stocks Likely to Outpace Q3 Earnings Estimates
Zacks via Yahoo Finance· 6 months agoAs we near the end of the ongoing earnings season, the scorecard for the Medical sector appears...
Europe Approves First CAR T-Cell Therapy For B-Cell Lymphoma In 30 Years to Improve Upon Standard of...
Benzinga via Yahoo Finance· 2 years agoThe European Commission approved Kite Pharma's, a Gilead Sciences Inc (NASDAQ: GILD) Yescarta...
Unveiling Gilead Sciences (GILD)'s Value: Is It Really Priced Right? A Comprehensive Guide
GuruFocus.com via Yahoo Finance· 8 months agoWith a daily gain of 1.82%, a three-month gain of 0.44%, and an Earnings Per Share (EPS) (EPS) of...
US Supreme Court Throws Out Bristol Myers Appeal On Cancer-Drug Related Patent With Gilead
Benzinga via Yahoo Finance· 2 years agoThe U.S. Supreme Court turned away an appeal made by rebuffed efforts made by Bristol Myers Squibb...
Gilead Sciences Inc's Dividend Analysis
GuruFocus.com via Yahoo Finance· 5 months agoGilead Sciences Inc (NASDAQ:GILD) recently announced a dividend of $0.75 per share, payable on 2023-12-28, with the ex-dividend date set for 2023-12-14....
Arcellx (RCLX) Down on Hold for Lead Program CART-ddBCMA
Zacks via Yahoo Finance· 11 months agoArcellx's (ACLX) study on lead program CART-ddBCMA for treating adult patients with relapsed or...
Arcellx Inc (ACLX) Q1 2024 Earnings: Narrower Losses and Revenue Surge
GuruFocus.com via Yahoo Finance· 2 weeks agoRevenue: Reported at $39.26 million for Q1 2024, an increase from $17.91 million in Q1 2023, surpassing estimates of $20.67 million. Net Loss: Recorded at $7.2 million for Q1 2024, significantly ...
FDA Demands "Boxed Warning" to CAR T-Cell Therapy Labels
Zacks via Yahoo Finance· 4 months agoThe FDA directs companies like NVS, BMY, GILD and others to add "boxed warning" to the labels of...